University Medical Center of the Johannes Gutenberg University Mainz

Across several large Perturb-seq datasets, a generative framework called Graph-guided Flow Matching (GFM) combines three biological knowledge graphs, covering Gene Ontology, protein interactions and perturbation similarity, with latent flow matching to predict single-cell transcriptomes after unseen perturbations. It outperforms a linear baseline and the deep-learning models CellFlow, GEARS and scGPT on unseen single-gene perturbations, trains up to 30 times faster, and keeps its advantage as training data shrink; on two-gene perturbations it does better when neither gene was seen in training.

Across several large Perturb-seq datasets, a generative framework called Graph-guided Flow Matching (GFM) combines three biological knowledge graphs, covering Gene Ontology, protein interactions and perturbation similarity, with latent flow matching to predict single-cell transcriptomes after unseen perturbations. It outperforms a linear baseline and the deep-learning models CellFlow, GEARS and scGPT on unseen single-gene perturbations, trains up to 30 times faster, and keeps its advantage as training data shrink; on two-gene perturbations it does better when neither gene was seen in training.

An international multidisciplinary working group of 41 experts systematically reviewed 922 citations up to March 17, 2025, revised the 2016 acute exacerbation (AE) definition—previously limited to idiopathic pulmonary fibrosis (IPF)—into an AE-fILD definition applicable across all fibrotic interstitial lung diseases (anchored in diffuse alveolar damage with or without organizing pneumonia), proposed the broader concept of acute respiratory worsening (ARW) to capture acute deteriorations not attributable to DAD, and summarized evidence on epidemiology, risk factors, prognosis, and management while discussing AE as a clinical trial endpoint.

An international multidisciplinary working group of 41 experts systematically reviewed 922 citations up to March 17, 2025, revised the 2016 acute exacerbation (AE) definition—previously limited to idiopathic pulmonary fibrosis (IPF)—into an AE-fILD definition applicable across all fibrotic interstitial lung diseases (anchored in diffuse alveolar damage with or without organizing pneumonia), proposed the broader concept of acute respiratory worsening (ARW) to capture acute deteriorations not attributable to DAD, and summarized evidence on epidemiology, risk factors, prognosis, and management while discussing AE as a clinical trial endpoint.